Tenapanor: A non-binder approach to phosphate control in chronic kidney disease

Written by The Life Science Feed Editorial Team · Edited by Mara Voss

Managing hyperphosphatemia in patients with chronic kidney disease (CKD) remains a persistent clinical challenge, particularly for those on dialysis. Elevated serum phosphate levels contribute significantly to mineral and bone disorders, vascular calcification, and increased mortality risk. Current therapeutic strategies, primarily phosphate binders, often face issues with adherence and gastrointestinal side effects, leaving a substantial unmet need for alternative approaches.

KEY TAKEAWAYS

- The Pivot: Tenapanor reduces phosphate absorption through a mechanism distinct from traditional phosphate binders, targeting the intestinal sodium-hydrogen exchanger 3.
- The Data: This novel mechanism leads to reduced paracellular phosphate uptake, offering an alternative for managing hyperphosphatemia.
- The Action: Clinicians should consider tenapanor as a potential option for hyperphosphatemia, particularly in patients struggling with conventional phosphate binders.

Patients with chronic kidney disease, especially those progressing to end-stage renal disease (ESRD) and requiring dialysis, frequently develop hyperphosphatemia. This condition, characterized by abnormally high serum phosphate levels, is not merely a laboratory abnormality. It drives a cascade of complications including secondary hyperparathyroidism, renal osteodystrophy, and accelerated cardiovascular disease, all of which contribute to the high morbidity and mortality observed in this population. The kidneys, in their healthy state, play a vital role in maintaining phosphate homeostasis by filtering and reabsorbing phosphate. As kidney function declines, this excretory capacity diminishes, leading to phosphate retention. Dietary phosphate restriction is a foundational intervention, but it is often insufficient on its own, necessitating pharmacological intervention.

The standard of care for hyperphosphatemia has long relied on phosphate binders. These agents work by binding to dietary phosphate in the gastrointestinal tract, forming insoluble complexes that are then excreted in the faeces, thereby preventing absorption. Available binders include calcium-based binders (e.g., calcium acetate, calcium carbonate), which are effective but carry a risk of hypercalcemia and vascular calcification, and non-calcium-based binders (e.g., sevelamer, lanthanum carbonate, ferric citrate), which mitigate the calcium burden but can be associated with their own set of gastrointestinal side effects such as constipation, nausea, and abdominal pain. The sheer pill burden associated with these binders, often requiring multiple pills with each meal, contributes significantly to poor patient adherence, limiting their real-world effectiveness. This adherence challenge highlights the need for therapies with different mechanisms of action and potentially improved tolerability profiles.

A novel mechanism of action

Tenapanor represents a departure from the traditional binder class, offering a distinct mechanism to reduce phosphate absorption. Instead of binding phosphate directly in the gut lumen, tenapanor acts as a small molecule inhibitor of the sodium-hydrogen exchanger 3 (NHE3). NHE3 is a primary transporter located on the apical membrane of enterocytes in the small intestine and colon, responsible for the electroneutral absorption of sodium and water. Its inhibition by tenapanor leads to a reduction in sodium absorption, which in turn increases luminal sodium and water content. This osmotic effect is thought to be a key driver of its primary indication in irritable bowel syndrome with constipation (IBS-C).

But the story with phosphate is more intricate. The reduction in sodium absorption and the subsequent increase in luminal fluid alter the paracellular pathway for phosphate absorption. Phosphate absorption in the intestine occurs through both transcellular and paracellular routes. While specific sodium-phosphate cotransporters (NaPi-IIb) mediate transcellular uptake, a significant portion of dietary phosphate is absorbed paracellularly, moving between enterocytes. This paracellular movement is largely driven by electrochemical gradients and solvent drag, influenced by the movement of water and other ions. By inhibiting NHE3, tenapanor disrupts the normal sodium and water flux across the intestinal epithelium, thereby reducing the driving force for paracellular phosphate absorption. This indirect modulation of phosphate transport, rather than direct binding, positions tenapanor as a unique therapeutic option.

Clinical implications for phosphate management

The clinical utility of tenapanor in hyperphosphatemia stems from this non-binder mechanism. For patients who struggle with the high pill burden, taste, or gastrointestinal side effects of conventional phosphate binders, tenapanor offers an alternative that could improve adherence and, consequently, phosphate control. Its action is independent of meal timing in

the same way binders are, as it targets an intrinsic intestinal transport mechanism rather than requiring direct interaction with food. This could simplify dosing regimens for some patients, although specific dosing instructions would still need to be followed.

The drug's effect on phosphate levels is dose-dependent, with studies showing reductions in serum phosphate. While specific numerical results are not available here, the consistent mechanism of action across various studies supports its role in phosphate management. The primary side effect observed with tenapanor is diarrhoea, which is a direct consequence of its NHE3 inhibitory action leading to increased luminal water. This side effect can be dose-limiting for some patients, requiring careful titration and patient education. But for many, this may be a more tolerable trade-off than the chronic constipation or bloating associated with some binders. The complex relationship between kidney health and systemic factors means that effective phosphate control can have far-reaching benefits beyond just bone health.

Comparing mechanisms and patient selection

The distinction between tenapanor and phosphate binders is critical for patient selection. Phosphate binders are essentially luminal scavengers. They require the presence of phosphate in the gut lumen to exert their effect, meaning they must be taken with meals. Their efficacy is directly tied to the amount of phosphate ingested and the binding capacity of the agent. Tenapanor, by contrast, modulates the absorptive physiology of the intestine itself. This difference suggests that tenapanor could be particularly beneficial for patients who have residual phosphate absorption despite optimal binder therapy, or for those who cannot tolerate binders. It also opens the door to combination therapy, where tenapanor could be used alongside a reduced dose of a phosphate binder to achieve better overall control with fewer side effects from either agent.

The long-term implications of sustained NHE3 inhibition on intestinal health are a consideration, though current data do not suggest major concerns beyond the expected gastrointestinal effects. The focus remains on the balance between phosphate reduction and tolerability. For clinicians, understanding this mechanistic difference is key to tailoring therapy. The promise of urinary exosomes in kidney disease diagnosis highlights the ongoing search for novel biomarkers and therapeutic targets in nephrology, and tenapanor's unique approach fits within this broader investigative trend.

Unanswered questions and future directions

While tenapanor offers a valuable addition to the hyperphosphatemia armamentarium, several questions remain.

The optimal positioning of tenapanor within existing treatment algorithms, particularly in combination with various phosphate binders, requires further elucidation. Head-to-head comparisons with non-calcium-based binders regarding efficacy, tolerability, and long-term outcomes would provide clearer guidance. Understanding which specific patient phenotypes respond best to tenapanor, beyond just those with binder intolerance, could refine prescribing practices. For example, patients with higher baseline paracellular phosphate absorption might see a more pronounced benefit. The role of tenapanor in pre-dialysis CKD patients, where phosphate restriction and binder use are also common, is another area of ongoing interest. The challenges in developing targeted therapies for specific kidney conditions underscore the complexity of renal drug development, and tenapanor's journey highlights the potential for novel mechanisms.

The open-label design of some early investigations is an obvious caveat, as is the focus on surrogate endpoints like serum phosphate levels rather than hard clinical outcomes such as cardiovascular events or mortality. While phosphate reduction is a well-established therapeutic goal, demonstrating a direct impact on patient-centric outcomes would

solidify tenapanor's role. The potential for drug-drug interactions, particularly with other agents that affect intestinal transport or fluid balance, also warrants careful consideration in a patient population often on multiple medications. For a comprehensive understanding of renal physiology and management, a resource like the Oxford Handbook of Nephrology and Hypertension remains invaluable for clinicians navigating these complex treatment guidelines.

CLINICAL IMPLICATIONS

Tenapanor's arrival in the hyperphosphatemia treatment landscape offers a genuine alternative to the long-standing dominance of phosphate binders. For clinicians, this means a new tool for patients who struggle with the high pill burden and gastrointestinal side effects that often plague adherence to conventional therapies. It is not a replacement for dietary restriction, but a complementary strategy that targets a different physiological pathway.

The mechanism of NHE3 inhibition, while effective for phosphate, does come with its own set of side effects, primarily diarrhoea. This necessitates careful patient selection and dose titration. But for many patients, a manageable increase in stool frequency might be preferable to the chronic constipation, bloating, or metallic taste associated with some binders, potentially improving their quality of life and, most importantly, their long-term phosphate control, which directly impacts cardiovascular and bone health.

From an industry perspective, the development of tenapanor highlights the value of exploring novel mechanisms for established therapeutic targets. It challenges the assumption that all phosphate-lowering agents must act as binders. This innovation could spur further research into other intestinal transport pathways that influence mineral metabolism, opening new avenues for drug development in nephrology.

The goal remains to reduce the cardiovascular and bone complications associated with hyperphosphatemia in CKD. Tenapanor provides another option in the clinician's arsenal, particularly for those patients where current strategies fall short. Its unique mechanism offers flexibility in treatment regimens, potentially allowing for better individualised care and improved adherence, which is often the silent killer of even the most effective therapies.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Rao IR, Bangera A, Nagaraju SP, et al. Chronic kidney disease of unknown aetiology: A comprehensive review of a global public health problem. Trop Med Int Health. 2023;28(8):588-600. doi:10.1111/tmi.13913
2. 2. Sarnak MJ, Amann K, Bangalore S, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(14):1823-1838. doi:10.1016/j.jacc.2019.08.1017
3. 3. Dang Z, He Y, Xie R, Chen P, Dong F. Plant-Based Diet and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. J Ren Nutr. 2025;35(4):517-530. doi:10.1053/j.jrn.2025.03.002
4. 4. Johnson HN, Prasad-Reddy L. Updates in Chronic Kidney Disease. J Pharm Pract. 2024;37(6):1380-1390. doi:10.1177/08971900241262381

5. 5. Narasaki Y, Kalantar-Zadeh K, Rhee CM, Brunori G, Zarantonello D. Vegetarian Nutrition in Chronic Kidney Disease. Nutrients. 2023;16(1). doi:10.3390/nu16010066

6. 6. Neuen BL, Yeung EK, Rangaswami J, Vaduganathan M. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrol Dial Transplant. 2025;40(Supplement_1):i59-i69. doi:10.1093/ndt/gfae258